Clinical Trial Update: A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes [Phase 3]

View source ↗

Summary

Phase 3 trial update for luspatercept (ACE-536) in anemia due to very low, low, or intermediate risk myelodysplastic syndromes has completed with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: COMPLETED | Results posted: 2020-05-22